{"id":282797,"date":"2025-12-11T16:58:00","date_gmt":"2025-12-11T22:58:00","guid":{"rendered":"https:\/\/dallasinnovates.com\/?p=282797"},"modified":"2025-12-12T15:24:06","modified_gmt":"2025-12-12T21:24:06","slug":"utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program","status":"publish","type":"post","link":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/","title":{"rendered":"UTSW Spinout InterAct Therapeutics Selected by Cell &#038; Gene Therapy Incubator Program"},"content":{"rendered":"<p><strong>Interact Therapeutics, a Dallas-based cancer cell and gene therapy company with links to UT Southwestern and Pegasus Park&#8217;s BioLabs, is one of six startups selected for the second cohort of Charles River Laboratories International&#8217;s Cell &amp; Gene Therapy Incubator Program (CIP).<\/strong><\/p>\n<p>InterAct, which launched inside BioLabs at Pegasus Park, is a preclinical stage biotech company developing AAV8-based gene therapies for metastatic cancer, with an initial focus on breast cancer-derived liver metastases (BC-LM).<\/p>\n<p>\u201cMetastasis accounts for approximately 90% of cancer deaths, and there is a gaping therapeutic void for patients with BC-LM, who face a survival window of just 3\u201315 months,&#8221; Daniel Hargrove, co-founder and CEO of InterAct Therapeutics, said in a statement. &#8220;The acceptance into the Charles River Incubator Program not only validates our novel AAV8 approach, but critically, it will accelerate the development and scale-up of our InterAct Print platform\u2014the real long-term value driver with true multi-indication optionality.\u201d\u00a0<\/p>\n<h3>Cracking the &#8216;biological code&#8217; on how tumor cells metastasize<\/h3>\n<p>Isaac Chan, the scientific leader of InterAct and a UTSW professor and researcher, said InterAct&#8217;s approach is a game-changer.<\/p>\n<p>\u201cFor the first time, we&#8217;re beginning to crack the biological code on how infiltrating tumor cells create space in distant organs,&#8221; added Chan, MD, PhD, co-founder and CSO of InterAct Therapeutics. &#8220;Our proprietary InterAct Print computational engine identified the essential genes driving liver colonization and therapeutic targets.&#8221;<\/p>\n<p>He also noted the importance of startup support, adding, &#8220;The Charles River Incubator provides the critical manufacturing and scientific support to translate this foundational discovery into a safe, durable, and liver-directed gene therapy for breast cancer liver metastases. We are honored to partner with Charles River.\u201d\u00a0<\/p>\n<p>In 2024, Chan was UT Southwestern&#8217;s principal investigator on a team that received a grant from Dallas-based breast cancer organization <a href=\"https:\/\/dallasinnovates.com\/susan-g-komen-announces-10m-in-grants-to-advance-breast-cancer-treatment-precision-medicine\/\">Susan G. Komen<\/a> for research on a treatment for metastatic breast cancer.<\/p>\n<h3>More on the Cell &amp; Gene Therapy Incubator Program<\/h3>\n<p>CIP launched in December 2024, with the\u00a0inaugural cohort announced in April 2025. The program gives early-stage biotechnology pioneers access to extensive scientific and commercial expertise, along with a comprehensive ecosystem of discovery, development, and manufacturing capabilities, to accelerate the development of technologies and life-changing therapies for patients in need.<\/p>\n<p>\u201cThe CIP\u2019s success shows how effectively it attracts top talent and promotes innovation,\u201d Kerstin Dolph, corporate SVP of global manufacturing at Charles River, said in a statement. \u201cBy establishing a strong foundation for commercial viability, the CIP is helping participants advance life-saving therapeutics and transform innovative ideas into real-world impact.\u201d<\/p>\n<p>InterAct is one of four advanced therapy developers in the cohort. The others are London-based <strong>CureAge Therapeutics<\/strong>, which is d<span data-olk-copy-source=\"MessageBody\">eveloping a platform to treat peripheral nerve diseases; San Diego-based <\/span><strong>Jaan Biotherapeutics<\/strong>, a developer of<span data-olk-copy-source=\"MessageBody\"> novel therapies designed to activate the cardiac regeneration process in diseased hearts using proprietary microRNA targeting technologies;<\/span> and <strong>Kopra<\/strong> <strong>Bio<\/strong>, a San Francisco start-up developing an\u00a0<i>in vivo<\/i> tumor editing platform targeting solid tumors with an initial focus on the most aggressive form of brain cancer, glioblastoma.<\/p>\n<p>Also in the cohort are two enabling technology developers: Columbia, Maryland-based <span data-olk-copy-source=\"MessageBody\">global supplier of specialty chemicals and pharmaceutical solutions<\/span> <strong>W.R. Grace &amp; Co.<\/strong>, which<span data-olk-copy-source=\"MessageBody\"> is advancing bioprocessing applications for its proprietary superparamagnetic silica technology in plasmid DNA production;<\/span> and <strong>HTLab AG\u2019s Biowerkli<\/strong>, a<span data-olk-copy-source=\"MessageBody\"> Swiss-based technology company that uses open source AI to empower the global biotech community with transparent, accessible AI, digitalization, and smart biomanufacturing tools to accelerate the development of safe, life-changing therapies for patients by turning disconnected data into a predictive engine for manufacturing and release success.<\/span>.<\/p>\n<p>According to Wilmington, Massachusetts-based Charles River Laboratories, program participants benefit from custom mentorship, regulatory and quality consultations, fit-for-purpose training initiatives, and preferential access to Charles River\u2019s global network of facilities, &#8220;curated to support cell and gene therapies from concept to cure.&#8221;<\/p>\n<hr style=\"border: none; height: 4px; background: #e5e5e5; margin: 20px 0; width: 100%;\" \/>\n<h2 style=\"font-size: 1.5rem; font-weight: 600; margin: 0 0 16px 0;\">Don&#8217;t miss what&#8217;s next. Subscribe\u00a0to\u00a0Dallas\u00a0Innovates.<\/h2>\n<p style=\"font-size: 1rem; line-height: 1.5; margin: 0 0 10px 0;\">Track Dallas-Fort Worth&#8217;s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.<\/p>\n<div id=\"mc_embed_signup\">\n<form id=\"mc-embedded-subscribe-form\" class=\"validate\" style=\"display: flex; flex-wrap: wrap; gap: 12px; align-items: center;\" action=\"https:\/\/dallasinnovates.us10.list-manage.com\/subscribe\/post?u=4797e7859e965c3dd288326a4&amp;id=7919fd325f\" method=\"post\" name=\"mc-embedded-subscribe-form\" novalidate=\"\" target=\"_blank\">\n<div id=\"mc_embed_signup_scroll\" style=\"display: flex; flex-wrap: wrap; gap: 12px; align-items: center;\">One quick signup, and you&#8217;re done.<\/p>\n<div style=\"display: flex; gap: 8px;\"><input id=\"mce-EMAIL\" class=\"email\" style=\"width: 300px; padding: 8px 12px; border: 1px solid #d1d5db; border-radius: 4px; font-size: 1rem;\" name=\"EMAIL\" required=\"\" type=\"email\" value=\"\" placeholder=\"email address\" \/> <input id=\"mc-embedded-subscribe\" class=\"button\" style=\"background-color: #4b0082; color: white; padding: 8px 20px; border: none; border-radius: 4px; cursor: pointer; font-weight: 500; transition: background-color 0.2s;\" name=\"subscribe\" type=\"submit\" value=\"Subscribe\" \/><\/div>\n<\/div>\n<\/form>\n<\/div>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>InterAct, which launched inside BioLabs at Pegasus Park, is a preclinical stage biotech company developing AAV8-based gene therapies for metastatic cancer, with an initial focus on breast cancer-derived liver metastases.<\/p>\n","protected":false},"author":467,"featured_media":282836,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[201981,12,15],"tags":[170952,10315,207961,994,208105,208405,189561,208398,179639,8410,208399,208404,208396,100856,208403,6940,208397,208395,208400,179640,208401,163600,163599,993,3777,208402],"class_list":["post-282797","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-discovery","category-invention","category-startup","tag-biotech-cancer","tag-biotech-startup","tag-breast-cancer-research","tag-cancer-research","tag-cancer-therapeutic","tag-cell-gene-therapy-incubator-program","tag-cell-and-gene-therapy","tag-charles-river","tag-charles-river-laboratories-international","tag-cip","tag-cureage-therapeutics","tag-daniel-hargrove","tag-dr-isaac-chan","tag-gene-therapy","tag-htlab-ags-biowerkli","tag-inc","tag-interact-therapeutics","tag-isaac-chan","tag-jaan-biotherapeutics","tag-kerstin-dolph","tag-kopra-bio","tag-spinout-ut-southwestern","tag-spinout-utsw","tag-ut-southwestern","tag-utsw","tag-w-r-grace-co-grace"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.6 (Yoast SEO v26.7) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>UTSW Spinout InterAct Therapeutics Selected by Cell &amp; Gene Therapy Incubator Program &#187; Dallas Innovates<\/title>\n<meta name=\"description\" content=\"InterAct Therapeutics incubator selection places the UTSW spinout in Charles River\u2019s Cell &amp; Gene Therapy Program to advance its AAV8 metastatic cancer platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UTSW Spinout InterAct Therapeutics Selected by Cell &amp; Gene Therapy Incubator Program\" \/>\n<meta property=\"og:description\" content=\"InterAct Therapeutics incubator selection places the UTSW spinout in Charles River\u2019s Cell &amp; Gene Therapy Program to advance its AAV8 metastatic cancer platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Dallas Innovates\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/dallasinnovates\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-11T22:58:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-12T21:24:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2025\/12\/InterActTherapeutics-2up-970.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"970\" \/>\n\t<meta property=\"og:image:height\" content=\"464\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandra Engelland\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@dallasinnovates\" \/>\n<meta name=\"twitter:site\" content=\"@dallasinnovates\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandra Engelland\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/\"},\"author\":{\"name\":\"Sandra Engelland\",\"@id\":\"https:\/\/dallasinnovates.com\/#\/schema\/person\/cde57bcc501e7c5e490f353cb44977a8\"},\"headline\":\"UTSW Spinout InterAct Therapeutics Selected by Cell &#038; Gene Therapy Incubator Program\",\"datePublished\":\"2025-12-11T22:58:00+00:00\",\"dateModified\":\"2025-12-12T21:24:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/\"},\"wordCount\":673,\"publisher\":{\"@id\":\"https:\/\/dallasinnovates.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2025\/12\/InterActTherapeutics-2up-970.jpg\",\"keywords\":[\"biotech cancer\",\"biotech startup\",\"breast cancer research\",\"cancer research\",\"cancer therapeutic\",\"Cell &amp; Gene Therapy Incubator Program\",\"cell and gene therapy\",\"Charles River\",\"Charles River Laboratories International\",\"CIP\",\"CureAge Therapeutics\",\"Daniel Hargrove\",\"Dr. Isaac Chan\",\"gene therapy\",\"HTLab AG\u2019s Biowerkli\",\"Inc\",\"InterAct Therapeutics\",\"Isaac Chan\",\"Jaan Biotherapeutics\",\"Kerstin Dolph\",\"Kopra Bio\",\"spinout ut southwestern\",\"spinout utsw\",\"UT Southwestern\",\"UTSW\",\"W.R. Grace &amp; Co. (Grace)\"],\"articleSection\":[\"Discovery\",\"Invention\",\"Startup\"],\"inLanguage\":\"en-US\",\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\/\/dallasinnovates.com\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/\",\"url\":\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/\",\"name\":\"UTSW Spinout InterAct Therapeutics Selected by Cell & Gene Therapy Incubator Program &#187; Dallas Innovates\",\"isPartOf\":{\"@id\":\"https:\/\/dallasinnovates.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2025\/12\/InterActTherapeutics-2up-970.jpg\",\"datePublished\":\"2025-12-11T22:58:00+00:00\",\"dateModified\":\"2025-12-12T21:24:06+00:00\",\"description\":\"InterAct Therapeutics incubator selection places the UTSW spinout in Charles River\u2019s Cell & Gene Therapy Program to advance its AAV8 metastatic cancer platform.\",\"breadcrumb\":{\"@id\":\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#primaryimage\",\"url\":\"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2025\/12\/InterActTherapeutics-2up-970.jpg\",\"contentUrl\":\"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2025\/12\/InterActTherapeutics-2up-970.jpg\",\"width\":970,\"height\":464,\"caption\":\"Left: Daniel Hargrove, co-founder and CEO of InterAct Therapeutics; Right: Isaac Chan, MD, PhD, Co-founder and CSO of InterAct Therapeutics [Photos: LinkedIn]\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dallasinnovates.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UTSW Spinout InterAct Therapeutics Selected by Cell &#038; Gene Therapy Incubator Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dallasinnovates.com\/#website\",\"url\":\"https:\/\/dallasinnovates.com\/\",\"name\":\"Dallas Innovates\",\"description\":\"What&#039;s new + next in Dallas - Fort Worth\",\"publisher\":{\"@id\":\"https:\/\/dallasinnovates.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dallasinnovates.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dallasinnovates.com\/#organization\",\"name\":\"Dallas Innovates | Published by Dallas Next\",\"url\":\"https:\/\/dallasinnovates.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dallasinnovates.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2018\/09\/Dallas-Innovates-logo-purple.jpg\",\"contentUrl\":\"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2018\/09\/Dallas-Innovates-logo-purple.jpg\",\"width\":1782,\"height\":410,\"caption\":\"Dallas Innovates | Published by Dallas Next\"},\"image\":{\"@id\":\"https:\/\/dallasinnovates.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/dallasinnovates\/\",\"https:\/\/x.com\/dallasinnovates\",\"https:\/\/www.instagram.com\/dallasinnovates\/\",\"https:\/\/www.linkedin.com\/company\/dallas-innovates\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/dallasinnovates.com\/#\/schema\/person\/cde57bcc501e7c5e490f353cb44977a8\",\"name\":\"Sandra Engelland\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dallasinnovates.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/03f0a72d240bd6101a0a168c49a4bcd31d8f18bf3f2d03a98c2e341ec1423793?s=96&d=retro&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/03f0a72d240bd6101a0a168c49a4bcd31d8f18bf3f2d03a98c2e341ec1423793?s=96&d=retro&r=g\",\"caption\":\"Sandra Engelland\"},\"sameAs\":[\"https:\/\/dallasinnovates.com\/sponsor\/capital-one\/\"],\"url\":\"https:\/\/dallasinnovates.com\/author\/sandra-engelland-2\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"UTSW Spinout InterAct Therapeutics Selected by Cell & Gene Therapy Incubator Program &#187; Dallas Innovates","description":"InterAct Therapeutics incubator selection places the UTSW spinout in Charles River\u2019s Cell & Gene Therapy Program to advance its AAV8 metastatic cancer platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/","og_locale":"en_US","og_type":"article","og_title":"UTSW Spinout InterAct Therapeutics Selected by Cell & Gene Therapy Incubator Program","og_description":"InterAct Therapeutics incubator selection places the UTSW spinout in Charles River\u2019s Cell & Gene Therapy Program to advance its AAV8 metastatic cancer platform.","og_url":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/","og_site_name":"Dallas Innovates","article_publisher":"https:\/\/www.facebook.com\/dallasinnovates\/","article_published_time":"2025-12-11T22:58:00+00:00","article_modified_time":"2025-12-12T21:24:06+00:00","og_image":[{"width":970,"height":464,"url":"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2025\/12\/InterActTherapeutics-2up-970.jpg","type":"image\/jpeg"}],"author":"Sandra Engelland","twitter_card":"summary_large_image","twitter_creator":"@dallasinnovates","twitter_site":"@dallasinnovates","twitter_misc":{"Written by":"Sandra Engelland","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#article","isPartOf":{"@id":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/"},"author":{"name":"Sandra Engelland","@id":"https:\/\/dallasinnovates.com\/#\/schema\/person\/cde57bcc501e7c5e490f353cb44977a8"},"headline":"UTSW Spinout InterAct Therapeutics Selected by Cell &#038; Gene Therapy Incubator Program","datePublished":"2025-12-11T22:58:00+00:00","dateModified":"2025-12-12T21:24:06+00:00","mainEntityOfPage":{"@id":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/"},"wordCount":673,"publisher":{"@id":"https:\/\/dallasinnovates.com\/#organization"},"image":{"@id":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#primaryimage"},"thumbnailUrl":"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2025\/12\/InterActTherapeutics-2up-970.jpg","keywords":["biotech cancer","biotech startup","breast cancer research","cancer research","cancer therapeutic","Cell &amp; Gene Therapy Incubator Program","cell and gene therapy","Charles River","Charles River Laboratories International","CIP","CureAge Therapeutics","Daniel Hargrove","Dr. Isaac Chan","gene therapy","HTLab AG\u2019s Biowerkli","Inc","InterAct Therapeutics","Isaac Chan","Jaan Biotherapeutics","Kerstin Dolph","Kopra Bio","spinout ut southwestern","spinout utsw","UT Southwestern","UTSW","W.R. Grace &amp; Co. (Grace)"],"articleSection":["Discovery","Invention","Startup"],"inLanguage":"en-US","copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/dallasinnovates.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/","url":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/","name":"UTSW Spinout InterAct Therapeutics Selected by Cell & Gene Therapy Incubator Program &#187; Dallas Innovates","isPartOf":{"@id":"https:\/\/dallasinnovates.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#primaryimage"},"image":{"@id":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#primaryimage"},"thumbnailUrl":"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2025\/12\/InterActTherapeutics-2up-970.jpg","datePublished":"2025-12-11T22:58:00+00:00","dateModified":"2025-12-12T21:24:06+00:00","description":"InterAct Therapeutics incubator selection places the UTSW spinout in Charles River\u2019s Cell & Gene Therapy Program to advance its AAV8 metastatic cancer platform.","breadcrumb":{"@id":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#primaryimage","url":"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2025\/12\/InterActTherapeutics-2up-970.jpg","contentUrl":"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2025\/12\/InterActTherapeutics-2up-970.jpg","width":970,"height":464,"caption":"Left: Daniel Hargrove, co-founder and CEO of InterAct Therapeutics; Right: Isaac Chan, MD, PhD, Co-founder and CSO of InterAct Therapeutics [Photos: LinkedIn]"},{"@type":"BreadcrumbList","@id":"https:\/\/dallasinnovates.com\/utsw-spinout-interact-therapeutics-selected-by-cell-gene-therapy-incubator-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dallasinnovates.com\/"},{"@type":"ListItem","position":2,"name":"UTSW Spinout InterAct Therapeutics Selected by Cell &#038; Gene Therapy Incubator Program"}]},{"@type":"WebSite","@id":"https:\/\/dallasinnovates.com\/#website","url":"https:\/\/dallasinnovates.com\/","name":"Dallas Innovates","description":"What&#039;s new + next in Dallas - Fort Worth","publisher":{"@id":"https:\/\/dallasinnovates.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dallasinnovates.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dallasinnovates.com\/#organization","name":"Dallas Innovates | Published by Dallas Next","url":"https:\/\/dallasinnovates.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dallasinnovates.com\/#\/schema\/logo\/image\/","url":"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2018\/09\/Dallas-Innovates-logo-purple.jpg","contentUrl":"https:\/\/dallasinnovates.com\/wp-content\/uploads\/2018\/09\/Dallas-Innovates-logo-purple.jpg","width":1782,"height":410,"caption":"Dallas Innovates | Published by Dallas Next"},"image":{"@id":"https:\/\/dallasinnovates.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/dallasinnovates\/","https:\/\/x.com\/dallasinnovates","https:\/\/www.instagram.com\/dallasinnovates\/","https:\/\/www.linkedin.com\/company\/dallas-innovates"]},{"@type":"Person","@id":"https:\/\/dallasinnovates.com\/#\/schema\/person\/cde57bcc501e7c5e490f353cb44977a8","name":"Sandra Engelland","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dallasinnovates.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/03f0a72d240bd6101a0a168c49a4bcd31d8f18bf3f2d03a98c2e341ec1423793?s=96&d=retro&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/03f0a72d240bd6101a0a168c49a4bcd31d8f18bf3f2d03a98c2e341ec1423793?s=96&d=retro&r=g","caption":"Sandra Engelland"},"sameAs":["https:\/\/dallasinnovates.com\/sponsor\/capital-one\/"],"url":"https:\/\/dallasinnovates.com\/author\/sandra-engelland-2\/"}]}},"_links":{"self":[{"href":"https:\/\/dallasinnovates.com\/wp-json\/wp\/v2\/posts\/282797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dallasinnovates.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dallasinnovates.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dallasinnovates.com\/wp-json\/wp\/v2\/users\/467"}],"replies":[{"embeddable":true,"href":"https:\/\/dallasinnovates.com\/wp-json\/wp\/v2\/comments?post=282797"}],"version-history":[{"count":0,"href":"https:\/\/dallasinnovates.com\/wp-json\/wp\/v2\/posts\/282797\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dallasinnovates.com\/wp-json\/wp\/v2\/media\/282836"}],"wp:attachment":[{"href":"https:\/\/dallasinnovates.com\/wp-json\/wp\/v2\/media?parent=282797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dallasinnovates.com\/wp-json\/wp\/v2\/categories?post=282797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dallasinnovates.com\/wp-json\/wp\/v2\/tags?post=282797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}